

REMARKS

Applicant respectfully requests that the foregoing amendments be made prior to examination of the present application.

After amending the claims as set forth above, claims 1-52 are now pending in this application.

Applicant believes that the present application is now in condition for allowance. Favorable consideration of the application as amended is respectfully requested.


The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date July 23, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By


Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Versions with Markings to Show Changes Made

Page 15 at lines 18, 21 and 23 with the following rewritten paragraphs respectively:

(145) N-[2-chloro-4-({6-methoxy-7-{{}}[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea

(146) N-[2-chloro-4-({7-{{}}[2-(1H-1-imidazolyl)-ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea

(148) N-[2-chloro-4-({6-methoxy-7-{{}}[2-(4-methyl-piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea.

Page 16 at lines 4, 12 and 24 with the following rewritten paragraphs respectively:

(160) N-[2-Chloro-4-({7-{{}}[4-(1H-1-imidazolyl)-butoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea

(164) N-[2-chloro-4-({6-methoxy-7-{{}}[3-(4-methyl-piperazino)propoxy]-4-quinazoliny]oxy)phenyl]-N'-(2,4-difluorophenyl)urea

(170) N-[2-chloro-4-({6-methoxy-7-{{}}[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-(2,4-difluorophenyl)urea.

IN THE CLAIMS:

21. (Amended) The compound according to claim 19 [or 20], wherein R³¹ represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl, or group R¹⁴-(S)_m- wherein R¹⁴ represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero); and p is an integer of 1 to 4.

22. (Amended) The compound according to [any one of claims 19 to 21] claim 19, wherein p is 1.

23. (Amended) The compound according to [any one of claims 19 to 21] claim 19, wherein R³¹ represents group R¹⁴-(S)m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero).

24. (Amended) The compound according to [any one of claims 19 to 21] claim 19, wherein R³¹ represents group R¹⁴-(S)m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero) and p is 1.

25. (Amended) The compound according to claim 23 [or 24], wherein R¹⁴ represents optionally substituted pyridyl.

28. (Amended) The compound according to claim 26 [or 27], wherein R³¹ represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl, or group R¹⁴-(S)m- wherein R¹⁴ represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero); and p is an integer of 1 to 4.

29. (Amended) The compound according to [any one of claims 26 to 28] claim 26, wherein p is 1.

30. (Amended) The compound according to [any one of claims 26 to 28] claim 26, wherein R³¹ represents group R¹⁴-(S)m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero).

31. (Amended) The compound according to [any one of claims 26 to 28] claim 26, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

32. (Amended) The compound according to claim 30 [or 31], wherein R^{14} represents optionally substituted pyridyl.

35. (Amended) The compound according to claim 33 [or 34], wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group $R^{14}-(S)_m-$ wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

36. (Amended) The compound according to [any one of claims 33 to 35] claim 33, wherein p is 1.

37. (Amended) The compound according to [any one of claims 33 to 35] claim 33, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

38. (Amended) The compound according to [any one of claims 33 to 35] claim 33, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

39. (Amended) The compound according to claim 37 [or 38], wherein R^{14} represents optionally substituted pyridyl.

42. (Amended) The compound according to claim 40 [or 41], wherein R³¹ represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl, or group R¹⁴-(S)m- wherein R¹⁴ represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero); and p is an integer of 1 to 4.

43. (Amended) The compound according to [any one of claims 40 to 42] claim 40, wherein p is 1.

44. (Amended) The compound according to [any one of claims 40 to 42] claim 40, wherein R³¹ represents group R¹⁴-(S)m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero).

45. (Amended) The compound according to [any one of claims 40 to 42] claim 40, wherein R³¹ represents group R¹⁴-(S)m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero) and p is 1.

46. (Amended) The compound according to claim 44 [or 45], wherein R¹⁴ represents optionally substituted pyridyl.

47. (Amended) The compound according to claim 1, which is a compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:

(13) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;

(51) N-(2-chloro-4-[[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy]phenyl)-N'-(2,4-difluorophenyl) urea;

(62) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea;

- (76) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-ethylurea;
- (117) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-methylurea;
- (119) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;
- (135) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea; (142) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (143) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (144) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (145) N-[2-chloro-4-({6-methoxy-7-({}[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
- (146) N-[2-chloro-4-({7-({}[2-(1H-1-imidazolyl)-ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;
- (148) N-[2-chloro-4-({6-methoxy-7-({}[2-(4-methyl-piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
- (149) N-(2-chloro-4-{[7-(2-hydroxyethoxy)-6-methoxy-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (151) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (152) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methyl-piperazino)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
- (153) N-[2-chloro-4-(6-methoxy-7-{[3-(1H-1,2,3-triazol-1-yl)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
- (157) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;
- (159) N-{2-chloro-4-[(6-methoxy-7-{[5-(1H-1,2,3-triazol-1-yl)pentyl]oxy}-4-quinolyl)oxy]phenyl}-N'-propylurea;
- (160) N-[2-chloro-4-({7-({}[4-(1H-1-imidazolyl)-butoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;

- (162) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-phenyl)urea;
- (163) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-phenyl)urea;
- (164) N-[2-chloro-4-{[6-methoxy-7-{[3-(4-methyl-piperazino)propoxy]-4-quinazolinyl]oxy}phenyl]-N'-(2,4-difluorophenyl)urea;
- (165) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinazolinyl)oxy]-phenyl}-N'-(2,4-difluorophenyl)urea;
- (168) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea;
- (169) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea;
- (170) N-[2-chloro-4-{[6-methoxy-7-{[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl]oxy}phenyl]-N'-(2,4-difluorophenyl)urea;
- (184) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-methylurea;
- (185) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-ethylurea; and
- (186) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea.

48. (Amended) A pharmaceutical composition comprising as active ingredient the compound according to [any one of claims 1 to 47] claim 1 or a pharmaceutically acceptable salt or solvate thereof.

50. (Amended) Use of the compound according to [any one of claims 1 to 47] claim 1 or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.

51. (Amended) A method for treating a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising the step of administering an effective amount of the compound according to [any one of claims 1 to 47] claim 1 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.

52. (Amended) A method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to [any one of claims 1 to 47] claim 1 or a pharmaceutically acceptable salt or solvate thereof in contact with vascular endothelial cells of the target blood vessels.

002.612929.1